Analysts Set Expectations for BioCardia FY2026 Earnings

BioCardia, Inc. (NASDAQ:BCDA) – Investment analysts at HC Wainwright decreased their FY2026 earnings per share estimates for shares of BioCardia in a report released on Thursday, March 26th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($0.71) per share for the year, down from their previous estimate of ($0.69). The consensus estimate for BioCardia’s current full-year earnings is ($3.52) per share.

BioCardia (NASDAQ:BCDA) last released its earnings results on Tuesday, March 24th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.14.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of BioCardia in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $25.00.

BioCardia Price Performance

Shares of BCDA stock opened at $1.16 on Monday. BioCardia has a 12 month low of $1.00 and a 12 month high of $3.20. The firm has a market cap of $12.69 million, a PE ratio of -0.90 and a beta of 0.60. The stock has a 50 day moving average of $1.23 and a 200-day moving average of $1.33.

Hedge Funds Weigh In On BioCardia

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. DRW Securities LLC acquired a new position in BioCardia in the 4th quarter valued at approximately $72,000. Geode Capital Management LLC grew its holdings in shares of BioCardia by 70.4% during the 4th quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock worth $83,000 after purchasing an additional 27,263 shares in the last quarter. Finally, Cetera Investment Advisers acquired a new stake in shares of BioCardia during the 2nd quarter worth approximately $40,000. 20.57% of the stock is currently owned by institutional investors.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.